DaVita Inc. (NYSE:DVA) Shares Bought by Forsta AP Fonden

Forsta AP Fonden lifted its holdings in DaVita Inc. (NYSE:DVA) by 2.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,000 shares of the company’s stock after purchasing an additional 900 shares during the period. Forsta AP Fonden’s holdings in DaVita were worth $5,738,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. increased its position in shares of DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares in the last quarter. Family Firm Inc. purchased a new position in shares of DaVita in the second quarter worth approximately $43,000. Versant Capital Management Inc increased its position in shares of DaVita by 90.6% in the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after acquiring an additional 155 shares in the last quarter. Friedenthal Financial purchased a new position in shares of DaVita in the second quarter worth approximately $48,000. Finally, Point72 Hong Kong Ltd purchased a new position in shares of DaVita in the second quarter worth approximately $68,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on DVA shares. UBS Group lifted their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. TD Cowen boosted their price objective on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Bank of America boosted their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Finally, Truist Financial boosted their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $159.00.

Insider Transactions at DaVita

In other news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the transaction, the chief financial officer now owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 173,482 shares of company stock worth $27,387,069. 2.00% of the stock is owned by insiders.

DaVita Price Performance

NYSE DVA opened at $157.05 on Tuesday. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. The stock has a market capitalization of $13.18 billion, a PE ratio of 16.73, a price-to-earnings-growth ratio of 0.90 and a beta of 0.87. The company has a 50 day moving average price of $158.18 and a two-hundred day moving average price of $145.85. DaVita Inc. has a 12-month low of $75.47 and a 12-month high of $168.50.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. The firm had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.08 earnings per share. As a group, equities analysts predict that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.